A reliable and sensitive reversed-phase high performance liquid chromatography (RP-HPLC) with ultraviolet (UV) detection method was developed and validated for the quantification of hopantenic acid in human plasma. Hopantenic acid, with protocatechuic acid as the internal standard (IS), was extracted from plasma samples using a liquid-liquid extraction with methanol. A chromatographic separation was achieved on a Luna C18 column (4.6 mm × 150 mm, 5-μm particle size) and precolumn of the same sorbent (2.0 mm). An isocratic elution, at a flow rate of 1.0 mL min−1, was used with a mobile phase consisting of acetonitrile, water, and 0.03% trifluoroacetic acid. The UV detector was set to 205 nm. The elution times for hopantenic acid and IS were ∼4.3 and 5.4 min, respectively. The calibration curve of hopantenic acid was linear (r > 0.9994) over the range of 0.5–100 μg mL−1 in human plasma. The limit of detection and limit of quantification for hopantenic acid were 0.034 and 0.103 μg mL−1, respectively. The present method was successfully applied for the estimation of pharmacokinetic parameters of hopantenic acid following single oral administration of tablets containing 250 mg hopantenic acid to healthy volunteers. For hopantenic acid, the data showed a mean maximum plasma concentration (Cmax) of 2.32 μg mL−1, with a time to reach peak plasma concentration (tmax) of 1.56 h.
[1]. N. Ogawa I. Nukina Y. Hirose M. Fukushima A. Mori 1985 Jpn. J. Pharmacol. 37 45–50.
[2]. S. Nakamura T. Takahashi Y. Sato 1972 Vitamins (Japan) 45 193–200.
[3]. Y. Umeno K. Nakai E. Matsushima T.J. Marunaka 1981 J. Chromatogr. 226 333–339.
[4]. K. Nakano H. Ando Y. Sugawara M. Ohashi S. Harigaya 1986 Drug Metab. Dispos. 14 740–745.
[5]. K. Banno M. Matsuoka S. Horimoto J. Kato 1990 J. Chromatogr. Biomed. Appl. 525 255–264.
[6]. K. Banno S. Horimoto M. Matsuoka 1991 J. Chromatogr. Biomed. Appl. 564 1–10.
[7]. K. Banno 1997 Methods Enzymol. 279 213–219.
[8]. R. Mittermayr A. Kalman M.J. Trisconi O. Heudi 2004 J. Chromatogr. A 1032 1–6.
[9]. H. Iwase 1993 Anal. Sci. 9 149–151.
[10]. O. Heudi P. Fontannaz 2005 J. Sep. Sci. 28 669–672.
[11]. M.V. Karlina O.N. Pozharitskaya A.N. Shikov V.M. Kosman M.N. Makarova V.G. Makarov 2008 Chromatographia 68 949–954.
[12]. O.N. Pozharitskaya M.V. Karlina A.N. Shikov V.M. Kosman M.N. Makarova V.G. Makarov 2009 Phytomedicine 16 244–251.
[13]. ICH, Q2A. Harmonised Tripartite Guideline, Text on Validation of Analytical Procedures, IFPMA. In: Proceedings of the International Conference on Harmonization, Geneva, 1994, pp. 1–5.
[14]. ICH, Q2B. Harmonised Tripartite Guideline, Validation of Analytical Procedure: Methodology, IFPMA. In: Proceedings of the International Conference on Harmonization, Geneva, 1996, pp. 1–8.
[15]. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, 2000.
[16]. European Agency for the Evaluation of Medicinal Products 2002 International Conference on Harmonisation. World Health Organization Guideline for Good Clinical Practice WHO Geneva, Switzerland.
[17]. M. Rowland T.N. Tozer 1995 Clinical Pharmacokinetics Lippincott Williams & Wilkins Philadelphia.
[18]. R. Ekinci C. Kadakal 2005 Acta Chromatogr. 15 289–297.
[19]. O. Heudi T. Kilinic P. Fontannaz 2005 J. Chromatogr. A 1070 49–56.
[20]. S.S. Boiko G.Iu. Vitskova V.P. Zherdev 1997 Eksp. Klin. Farmakol. 60 62–70.